Boston Scientific Closes Claret Medical Acquisition and Receives CMS Reimbursement Designation


August 2, 2018—Boston Scientific Corporation announced that it has closed its acquisition of Claret Medical, Inc., which has developed and commercialized the Sentinel cerebral embolic protection system to protect patients from the risk of stroke in transcatheter aortic valve replacement procedures. Additionally, the company announced that the Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) designation for the Sentinel system as part of the federal fiscal year 2019 Inpatient Prospective Payment System.

On July 20, Boston Scientific announced a definitive agreement to acquire Claret Medical for $220 million in up-front cash with an additional $50 million payment for reaching a reimbursement-based milestone, which has been fulfilled with the NTAP designation. The NTAP designation is awarded to new medical devices determined to substantially improve the diagnosis or treatment of Medicare beneficiaries and will be effective on October 1, 2018.

The Sentinel system received European CE Mark approval in 2014 and FDA clearance in 2017.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.